ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 438 participants.
Also called NCT05070260
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 438 participants
- Sponsor
- Acticor Biotech
- Registry
-
NCT05070260
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Germany
- Registry status
- Completed
Technical summary
Registry record NCT05070260. Randomized; triple masking; primary purpose treatment. Start 2021-09-23 (actual); primary completion 2024-04-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
- Acronym
- ACTISAVE
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Intravenous glenzocimab (ACT017) 1000 mg
- Intervention (Drug)
- Intravenous Placebo
- Lead sponsor
- Acticor Biotech
Record details
- Record id
cardio:ct-nct05070260- Content hash
a7e0cf7d42b0bc97c25d244125e67b21c8fd4b503bb01d769eab38e244aa6470